BRIEF-LAVA Doses First Patient In Phase 1 LAVA-1266 Study In Hematological Cancers

Reuters
10 Jan
BRIEF-LAVA Doses First Patient In Phase 1 LAVA-1266 Study In Hematological Cancers

Jan 10 (Reuters) - LAVA Therapeutics NV LVTX.O:

  • LAVA DOSES FIRST PATIENT IN PHASE 1 LAVA-1266 STUDY IN HEMATOLOGICAL CANCERS

  • LAVA THERAPEUTICS NV: INITIAL PHASE 1 DATA READ-OUT EXPECTED BY YEAR-END 2025

Source text: nGNXcbcydx

Further company coverage: LVTX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10